XCHC FULL COURT PRESS//'American Drug War II: Cannabis

New Post Public Reply Private Reply Replies (0) Message Board
Compensated Post
shakerzzz

XCHC >FULL COURT PRESS//'American Drug War II: Cannabis Destiny' is IMDB's Highest Rated 2013 Documentary


COLORADO SPRINGS, Colo., July 8, 2013 /PRNewswire/ -- The X-Change Corporation (NASDAQ OTC: XCHC), a U.S. Company specializing primarily in cannabinoid formulation-based health and wellness solutions, is proud to announce that "American Drug War II:  Cannabis Destiny" rated as the highest of all 2013 documentaries with a score of 9.7 out of 10.

The film focuses on the failed U.S. drug war and its affect on a new generation of children.  As IMDB states, "Director Kevin Booth navigates through the cutting edge of Cannabis research while becoming a foster parent to a child court ordered to take powerful mind altering drugs."

http://www.imdb.com/search/title?sort=user_ra...=2013,2013

CFO and SR VP of Business Development of X-Change Corp, Robert Kane, stated, "It has been one of the greatest professional experiences of my life to work with Kevin Booth and his team.  It is a privilege to be part of the project from the inception of the business plan, through production and release.  To have it #1 on this year's IMDB highest rated documentary list is telling of the quality of production and the power of the film's message.  This is important because the story speaks to our country's failed drug policy within a context of inhumane effects on children in need of treatment.   We are thankful that the documentary includes the poignant story of little Cash Hyde.   The interest in this film is a game changing moment for both the film and entertainment industry as well as the Cannabis industry as the film's success establishes that the market is primed for further investment from media and entertainment giants to support, fund, and invest in related projects."

The film is available on DirecTV Video on Demand.  It is also available on iTunes:  https://itunes.apple.com/us/movie/american-drug-war-2-cannabis/id635644281?ls=1.  In addition, it is available as a Video on Demand from Amazon:  http://www.amazon.com/American-Drug-War-Cannabis-Destiny/dp/B00CO0LPWG/ref=sr_1_20?s=instant-video&ie=UTF8&qid=1370536759&sr=1-20.

About The X-Change Corporation

The X-Change Corporation is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the hemp plant. Medicinal properties of hemp have been known and applied for thousands of years.  With the aid of scientific research The X-Change Corporation is translating such knowledge into development of effective cosmeceutical, nutraceutical, and food brands throughout the world. The Company's cosmetics and nutritional lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

X-Change Corp.

President

Dr. Dorothy Bray

info@xchangecorp.com

www.xchangecorp.com

1.866.326.5595

Investment Inquiries

Robert Kane

CFO, Sr Vp of Business Development

rkane@xchangecorp.com

561.420.4824

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 92

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 147

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 143

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 303

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 185

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 292

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 96

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 146

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 239

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights on CDW's Market Position and P/E Ratio Analysis

Updated Category News Views 123

Analyzing CDW's Current Market Performance CDW Inc.'s current stock price stands at $164.29, reflecting a notable increase of 2.59% during the ongoing market session. Despite this uptick, shareholders might be concerned as the stock has experienced a decline of 6.53% over the past month and a more significant drop of 24.18% over the last year. With these figures, it...

Continue Reading
What the Recent Earnings Report Means for FactSet Research

Updated Category News Views 135

FactSet Research Exceeds Expectations in Q1 Performance FactSet Research Systems Inc. (NYSE: FDS) has reported first-quarter results that exceeded analyst expectations, showcasing strong performance in a competitive financial market. The company achieved first-quarter sales totaling $607.6 million, surpassing the anticipated $600.5 million, which reflects a commendable...

Continue Reading
Dime Community Bancshares Unveils Executive Transition Plans

Updated Category News Views 180

Dime Community Bancshares Executive Changes Dime Community Bancshares, Inc. (NASDAQ: DCOM) recently announced significant changes in its leadership team as part of a strategic succession plan. This initiative reflects the company’s commitment to fostering a robust executive structure and enhancing its operational growth. Leadership Transition Details As Dime prepares...

Continue Reading
Hygiene Products Industry on Track to Reach $14.62 Billion

Updated Category News Views 112

Overview of the Antiseptic Products Market The global antiseptic products market is projected to experience remarkable growth, reaching an estimated value of USD 10.85 billion in 2025, and anticipated to climb to USD 14.62 billion by 2032. This represents a compound annual growth rate (CAGR) of 4.35% during the period. As health-conscious consumers become increasingly...

Continue Reading
China's Enduring Commitment to Global Peace and Prosperity

Updated Category News Views 91

China's Historical Role in the UN The United Nations (UN) stands as a testament to humanity's resolve for peace, shaped significantly by historical events like the World Anti-Fascist War. This war saw the Allies, including China, rally against the Axis powers, fostering a crucial international alliance. Founded as a result of collective victories, the UN embodies the...

Continue Reading